Good evening :)
$
₹
F

Fortrea Holdings Inc.

FTRE

NASDAQ
F

Fortrea Holdings Inc.

FTRE

NASDAQ
$21.937.20% (+1.47)
$
₹
$21.937.20% (+1.47)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $2.0B the stock is ranked 2158

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

3.79
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.73
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0.34
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-2.58%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 13 analysts reports

Buy
7 analysts
Hold
4 analysts
Sell
2 analysts

Price Upside

+13.42%

Earnings Growth

+104.31%

Rev. Growth

-1.64%

See Detailed Forecast

Company Profile

Company Profile

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
P/E Ratio
37.24
37.24
1Y Return
19.25%
19.25%
Buy Reco %
85.18
85.18
Agilent Technologies Inc
A
Agilent Technologies Inc
P/E Ratio
34.60
34.60
1Y Return
20.71%
20.71%
Buy Reco %
68.18
68.18
Waters Corporation
WAT
Waters Corporation
P/E Ratio
195.64
195.64
1Y Return
21.8%
21.8%
Buy Reco %
78.26
78.26
IQVIA Holdings Inc
IQV
IQVIA Holdings Inc
P/E Ratio
32.18
32.18
1Y Return
25.54%
25.54%
Buy Reco %
90.00
90.00
Illumina Inc
ILMN
Illumina Inc
P/E Ratio
38.99
38.99
1Y Return
85.02%
85.02%
Buy Reco %
47.61
47.61
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 13.42% growth, versus a trailing 3-year CAGR of -11.16%.

2026
Current$20.83Baseline
Analyst Target - 1 year
Target$23.63+13.42%

All values in $

20232024202520262027$21.24$26.96$32.67Target+13.42%
2026
Current$20.83Baseline
Analyst Target - 1 year
Target$23.63+13.42%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -1.64% growth, versus a trailing 3-year CAGR of -1.35%.

2025
Current$2.72Baseline
Forecast for Dec 2026
High$2.68-1.29%
Average$2.67-1.64%
Low$2.66-2.14%

All values in $ Billion

2021202220232024202520263.052.832.842.692.72Low-2.14%Average-1.64%High-1.29%
2025
Current$2.72Baseline
Forecast for Dec 2026
High$2.68-1.29%
Average$2.67-1.64%
Low$2.66-2.14%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$0.42Baseline
Forecast for Dec 2026
High$0.91+117.76%
Average$0.86+104.31%
Low$0.81+92.86%

All values in $

20222023202420252026N/A1.40.340.42Low+92.86%Average+104.31%High+117.76%
2025
Current$0.42Baseline
Forecast for Dec 2026
High$0.91+117.76%
Average$0.86+104.31%
Low$0.81+92.86%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

660.5
-32.5
636.5
-23.6
678.2
-13.2
691.5
0.6
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue662.4674.9697651.3710.3701.3660.5636.5678.2691.5
Net Income-138.4-27.9-61.2-562.9-374.9-15.9-32.5-23.6-13.20.6
Net Profit Margin-20.89%-4.13%-8.78%-86.42%-52.78%-2.26%-4.92%-3.70%-1.94%0.08%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Fortrea Holdings Inc. -3.790.34
Thermo Fisher Scientific Inc37.244.722.02
Agilent Technologies Inc34.606.711.48
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare FTRE with any stock or ETF
Compare FTRE with any stock or ETF
Comparing from
FTRE
TMO
A
Loading...

Frequently asked questions

  1. Fortrea Holdings Inc. (FTRE) share price today is $21.93 as of November 6, 2026 at 8:38 PM IST. The stock touched a day high of $21.93 and a day low of $20.40.

  2. Fortrea Holdings Inc. stock trades on NASDAQ under the ticker symbol FTRE.

  3. Fortrea Holdings Inc.'s market capitalization is $2.01B as of November 6, 2026 at 8:38 PM IST.

  4. Fortrea Holdings Inc.'s price-to-earnings (P/E) ratio is N/A as of November 6, 2026.

  5. Fortrea Holdings Inc.'s price-to-book (P/B) ratio is 3.79 as of November 6, 2026.

  6. Yes, You can buy Fortrea Holdings Inc. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Fortrea Holdings Inc. shares in three steps: 1. Search Fortrea Holdings Inc. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Fortrea Holdings Inc. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Fortrea Holdings Inc. (FTRE) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.4558 shares at the current price of $21.93.

Loading...